Medicine and Dentistry
Biological Marker
25%
Breast Cancer
25%
Cancer Tissue
8%
Cetuximab
33%
Colorectal Carcinoma
8%
Combination Therapy
8%
Dimer
58%
Disease Exacerbation
8%
Energy Transfer
33%
Epidermal Growth Factor Receptor
16%
Epidermal Growth Factor Receptor 2
16%
Fluorescence Microscopy
33%
Fluorescence-Lifetime Imaging Microscopy
100%
Fluoropyrimidine
8%
Hazard Ratio
25%
Heterodimer
50%
Latent Class Analysis
16%
Lifespan
33%
Metastatic Breast Cancer
33%
Overall Survival
33%
Oxaliplatin
16%
Pertuzumab
16%
Primary Tumor
8%
Progression Free Survival
8%
Targeted Therapy
16%
Tissue Microarray
41%
Trastuzumab
8%
Treatment Response
8%
Tumor Progression
8%
Biochemistry, Genetics and Molecular Biology
Cetuximab
33%
Dimerization
50%
Energy Transfer
33%
Epidermal Growth Factor Receptor
16%
Fluorescence Microscope
33%
Fluorescence Microscopy
33%
Fluorescence Resonance Energy Transfer
33%
Fluorescence-Lifetime Imaging Microscopy
100%
Genetics
8%
Lifespan
33%
Overall Survival
33%
Pertuzumab
22%
Progression Free Survival
8%
Radiation Beam
33%
Statistical Test
8%
Tissue Microarray
44%
Trastuzumab
11%
Tumor Progression
11%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
25%
Breast Cancer
25%
Cetuximab
33%
Chemotherapy
33%
Colorectal Carcinoma
8%
Combination Therapy
8%
Dimer
58%
Disease Exacerbation
8%
Epidermal Growth Factor Receptor
16%
Epidermal Growth Factor Receptor 2
16%
Fluorescence-Lifetime Imaging Microscopy
66%
Fluoropyrimidine
8%
Heterodimer
50%
Metastatic Breast Cancer
33%
Overall Survival
33%
Oxaliplatin
16%
Pertuzumab
16%
Primary Tumor
8%
Progression Free Survival
8%
Trastuzumab
8%
Tumor Growth
8%
